about
Adenoviral vectors for prodrug activation-based gene therapy for cancerMucin-based targeted pancreatic cancer therapyCrystal Structure of the Geobacillus stearothermophilus Carboxylesterase Est55 and Its Activation of Prodrug CPT-11Towards fibroid gene therapy: adenovirus-mediated delivery of herpes simplex virus 1 thymidine kinase gene/ganciclovir shrinks uterine leiomyoma in the Eker rat model.Mutant sodium channel for tumor therapy.Transfection of oocytes and other types of ovarian cells in rabbits after direct injection into uterine arteries of adenoviruses and plasmid/liposomes.Development of a fluorescence-based, ultra high-throughput screening platform for nanoliter-scale cytochrome p450 microarrays.Monitoring enzyme activity using a diamagnetic chemical exchange saturation transfer magnetic resonance imaging contrast agent.Gliomagenesis and the use of neural stem cells in brain tumor treatmentTomato thymidine kinase-based suicide gene therapy for malignant glioma--an alternative for Herpes Simplex virus-1 thymidine kinase.Direct evidence for the participation of gap junction-mediated intercellular communication in the transmission of damage signals from alpha -particle irradiated to nonirradiated cells.Gene therapy and targeted toxins for glioma.Gene therapy of hepatocarcinoma: a long way from the concept to the therapeutical impact.Role of glutamate 64 in the activation of the prodrug 5-fluorocytosine by yeast cytosine deaminase.Neural precursor cells and their role in neuro-oncology.In vivo activity in a catalytic antibody-prodrug system: Antibody catalyzed etoposide prodrug activation for selective chemotherapyOncolytic viral therapies - the clinical experience.Stem and progenitor cell-mediated tumor selective gene therapy.Prodrug approaches for CNS deliveryImproved Adeno-associated Viral Gene Transfer to Murine Glioma.Applications of neural and mesenchymal stem cells in the treatment of gliomas.Novel treatment strategies for malignant gliomas using neural stem cells.Cell-interdependent cisplatin killing by Ku/DNA-dependent protein kinase signaling transduced through gap junctions.Sitimagene ceradenovec: a gene-based drug for the treatment of operable high-grade glioma.Combining conditionally replicating adenovirus-mediated gene therapy with chemotherapy: a novel antitumor approach.Encapsulated cell grafts to treat cellular deficiencies and dysfunction.Recent developments in oncolytic adenovirus-based immunotherapeutic agents for use against metastatic cancers.The future of prodrugs - design by quantum mechanics methods.Prodrugs design based on inter- and intramolecular chemical processes.Preclinical anatomical, molecular, and functional imaging of the lung with multiple modalities.Using predrugs to optimize drug candidates.Gene-directed enzyme prodrug therapy.Targeted prodrug approaches for hormone refractory prostate cancer.Non-invasive 19F MR spectroscopy of 5-fluorocytosine to 5-fluorouracil conversion by recombinant Salmonella in tumours.Adenovirus-mediated hypoxia-targeted gene therapy using HSV thymidine kinase and bacterial nitroreductase prodrug-activating genes in vitro and in vivo.Expression of the reporter genes lacZ and EGFP in human glioblastoma cells using Listeria monocytogenes as vector for gene transfer.In vitro evaluation of cancer-specific NF-kappaB-CEA enhancer-promoter system for 5-fluorouracil prodrug gene therapy in colon cancer cell lines.Fusion of the HSV-1 tegument protein vp22 to cytosine deaminase confers enhanced bystander effect and increased therapeutic benefit.A neuroblastoma-selective suicide gene therapy approach using the tyrosine hydroxylase promoter.Herpes simplex virus thymidine kinase/ganciclovir system in multicellular tumor spheroids.
P2860
Q26860729-DFE6AD17-BE9A-4381-8586-D455D8684515Q26861761-E9A5E832-2DF9-4EC5-9DF8-B5DD69788DE1Q27641256-1EFA3D3F-7BA9-459F-9648-3E89B79F06ACQ30395754-4769A2AB-522D-48A5-A04F-1973A03C49CFQ30481753-D74CD6D0-98E5-4FF5-97D2-056A0E56D806Q30901473-154ACF74-FF70-46D3-914B-5267BFEF3FE0Q33467340-AE2F8E73-1E5A-44E4-8E60-AC44D00EF5BAQ34020035-C532636E-0E4A-4F95-A70F-0700E2D0CBAFQ34310698-79A295A4-9E9E-4CD3-95E9-FC98943ACC84Q34459264-7A7125EA-CC56-4548-93C0-28CF03A5D590Q34609590-3F2C2F7A-A136-4E4C-B02B-5A36FC0A482BQ35118933-0731B28A-27BD-4002-88A1-9FF7CB8B945DQ35208038-48903718-16FF-4449-BAC3-D794A875EED7Q35738728-D9B2F3E0-F015-466D-B074-D254A17135F1Q36041769-BB5EFBA3-B86A-4C9B-AC2D-A4C3F518C869Q36314064-B2D3D9E0-5353-44FA-98E4-BD8EC83A968DQ36318202-3D9D6C59-FBB2-479A-83E2-E6191B116B5AQ37120161-6219329C-ADFE-4CC2-9BEB-2F030B149456Q37150860-E2E1FC0F-A600-4B0D-AE65-1F2B0BB787B2Q37366610-5D0D7267-3E3B-46E1-98BE-8804E6E40F7CQ37483966-75F1213E-61AE-4BEE-B511-7E68C425FC4FQ37533630-DA71529E-F5EB-4A8E-BD6F-1E2FCD3A336AQ37647252-2500BB24-05B3-495D-AA59-E6DE5A27623FQ37818222-3823EDEC-C100-4E53-AD20-61A9DFAD968EQ37867584-857D4BA0-D0BC-4413-8B44-6320E44415CCQ37971089-B03AAFC3-CE70-4CA7-B8D5-DDEDE6AC95A8Q38073096-20E89E3D-5B44-462A-818A-001B4F10FB95Q38094262-3A442EF1-9280-4F9C-A0F2-CD38C8B46DF7Q38133663-8A92DF29-BA8C-48F7-92EB-138C6F2CCAABQ38198485-3564CCD8-3A2B-4E1E-99B3-68ED2B2D1D62Q38243993-2A04B053-F09A-4543-8A5E-755C3236E9BAQ38262019-811875C8-C7DF-42CB-ADEE-A0F61E78AED5Q38295983-9B4C5E33-FC60-480B-9D30-68E87B072C65Q38603044-E2CA7BC6-E0AD-45D0-987F-2F7322FA8263Q39491365-E6B15D1E-B272-441B-A45E-BD03983721DFQ39884121-E192E60E-313C-499F-80E4-6BA321714487Q40096386-5215C520-E297-400A-97D1-E1FA24CCCCC4Q40373403-9763C749-B0F9-41D9-A54C-F8F90548248BQ40548567-A659187B-1522-424C-A1CD-2FF6DF849E92Q40563109-D33BDB82-5A60-413E-91E2-1B1C92A39B36
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Prodrug activation enzymes in cancer gene therapy.
@ast
Prodrug activation enzymes in cancer gene therapy.
@en
type
label
Prodrug activation enzymes in cancer gene therapy.
@ast
Prodrug activation enzymes in cancer gene therapy.
@en
prefLabel
Prodrug activation enzymes in cancer gene therapy.
@ast
Prodrug activation enzymes in cancer gene therapy.
@en
P2093
P2860
P1476
Prodrug activation enzymes in cancer gene therapy.
@en
P2093
Breakefield XO
Hochberg F
P2860
P304
P356
10.1002/(SICI)1521-2254(200005/06)2:3<148::AID-JGM105>3.0.CO;2-Q
P577
2000-05-01T00:00:00Z